Results 181 to 190 of about 18,378,232 (237)

Noninvasive prediction of clinically significant portal hypertension in metabolic dysfunction-associated steatotic liver disease compared to other chronic liver diseases. [PDF]

World J Hepatol
Masood M, Thandassery RB.
europepmc   +1 more source

HLA‐A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection

Alimentary Pharmacology &Therapeutics, EarlyView.
The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...
Maria Francesca Cortese, Adriana Palom, Ariadna Rando Segura, Francesc Rudilla, Emma Enrich Rande, Arnau Puig Lopez, David Tabernero Caellas, Judit Vico Romero, Juan Carlos Ruiz‐Cobo, Mar Riveiro‐Barciela, Maria José Herrero, Maria Buti   +11 more
wiley   +1 more source

Assessment of liver stiffness measurement-related markers in predicting liver-related events in viral cirrhosis with clinically significant portal hypertension. [PDF]

World J Hepatol
Li YQ, Li YQ, Li JZ, Zhu BB, Lu Y, Feng Y, Wang XB.   +6 more
europepmc   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Uceda Renteria, Mariapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source

Indocyanine Green Retention Rate at 15 Minutes as a Key Predictor of Clinically Significant Portal Hypertension in Cirrhosis: Development and Validation of a Superior Non-Invasive Diagnostic Model. [PDF]

Turk J Gastroenterol
Hu H, Lai W, Zhou T, Zhu J, Yan H.
europepmc   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” [PDF]

Clinical and Molecular Hepatology
Haiyu Wang, Jinjun Chen
doaj   +1 more source

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

British Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli, Alessia Campagna, Barbara Eramo, Christian Sepe, Annarita Zuena, Silvana Gaetani, Adele Romano   +6 more
wiley   +1 more source

Clinically significant portal hypertension in cirrhosis patients with COVID-19: Clinical characteristics and outcomes. [PDF]

J Infect, 2020
Liu F, Long X, Ji G, Zhang B, Zhang W, Zhang Z, Chen X.   +6 more
europepmc   +1 more source

A CECT‐Based 2PI System as a Novel Noninvasive Prognostic Tool for Hepatocellular Carcinoma: A Dual‐Validation Study

Cancer Science, EarlyView.
Using differential weighting, we developed a 2PI‐based risk stratification system for HCC recurrence. A comprehensive prognostic model incorporating clinical variables and the 2PI score further enhanced postoperative prediction in solitary HCC and showed initial generalizability across SR and RFA cohorts.
Yingzhu Cui, Dezhi Zhang, Fan Lin, Liang Guo, Lei Zhang, Kan He, Hongbin Wang, Shuang Zheng, Kun Zhang, Yu Fu, Huimao Zhang   +10 more
wiley   +1 more source